Results 141 to 150 of about 1,848 (184)

Antihypertensive/selexipag

Reactions Weekly, 2022
openaire   +1 more source

Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE

Journal of Heart and Lung Transplantation, 2021
Kristin Highland, Harrison W Farber, Kelly M Chin   +2 more
exaly  

Selexipag/warfarin

Reactions Weekly, 2022
openaire   +1 more source

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects

British Journal of Clinical Pharmacology, 2021
Juan José Perez-Ruixo, Lene Nygaard Axelsen, Freya Rasschaert   +2 more
exaly  

Macitentan/selexipag

Reactions Weekly, 2022
openaire   +1 more source

Selexipag/treprostinil

Reactions Weekly, 2023
openaire   +1 more source

Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis.

Pulmonary Pharmacology and Therapeutics, 2022
Cheng Hong, Minshan Chen, Donghao Wang
exaly  

Selexipag

Reactions Weekly, 2018
openaire   +1 more source

Magnesium/selexipag

Reactions Weekly, 2021
openaire   +1 more source

Epoprostenol/selexipag

Reactions Weekly, 2020
openaire   +1 more source